Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials

References

• Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosisAm J Med1993946466508506892
   PubMed Web of Science ®Google Scholar
• Funck-BrentanoTBiverEChopinFClinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic reviewSemin Arthritis Rheum20114115716921507464
   PubMed Web of Science ®Google Scholar
• KunchurRNeedAHughesTGossAClinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jawsJ Oral Maxillofac Surg2009671167117319446200
   PubMed Web of Science ®Google Scholar
• LewieckiEMBenefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosisCurr Osteoporos Rep20108152220425086
   PubMedGoogle Scholar
• OkamotoKInabaMFurumitsuYBeneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal studyLife Sci20108768669120951147
   PubMed Web of Science ®Google Scholar
• van LeeuwenJPvan DrielMvan den BemdGJPolsHAVitamin D control of osteoblast function and bone extracellular matrix mineralizationCrit Rev Eukaryot Gene Expr20011119922611693961
   PubMed Web of Science ®Google Scholar
• LangubMCReinhardtTAHorstRLMallucheHHKoszewskiNJCharacterization of vitamin D receptor immunoreactivity in human bone cellsBone20002738338710962349
   PubMed Web of Science ®Google Scholar
• MeeAPHoylandJABraidmanIPFreemontAJDaviesMMawerEBDemonstration of vitamin D receptor transcripts in actively resorbing osteoclasts in bone sectionsBone1996182952998726384
   PubMed Web of Science ®Google Scholar
• BrommageRDeLucaHFEvidence that 1,25-dihydroxyvitamin D3 is the physiologically active metabolite of vitamin D3Endocr Rev198564915113000754
   PubMed Web of Science ®Google Scholar
• KhoslaSMinireview: the OPG/RANKL/RANK systemEndocrinology20011425050505511713196
   PubMed Web of Science ®Google Scholar
• DeLucaHFOverview of general physiologic features and functions of vitamin DAm J Clin Nutr2004801689S1696S15585789
   PubMed Web of Science ®Google Scholar
• NishiiYActive vitamin D and its analogs as drugs for the treatment of osteoporosis: advantages and problemsJ Bone Miner Metab200220576511862526
   PubMed Web of Science ®Google Scholar
• NishiiYRationale for active vitamin D and analogs in the treatment of osteoporosisJ Cell Biochem20038838138612520540
   PubMed Web of Science ®Google Scholar
• NishiiYOkanoTHistory of the development of new vitamin D analogs: studies on 22-oxacalcitriol (OCT) and 2beta-(3-hydroxypropoxy) calcitriol (ED-71)Steroids20016613714611179721
   PubMed Web of Science ®Google Scholar
• BouillonROkamuraWHNormanAWStructure-function relationships in the vitamin D endocrine systemEndocr Rev1995162002577781594
   PubMed Web of Science ®Google Scholar
• OkudaNTakedaSShinomiyaKED-71, a novel vitamin D analog, promotes bone formation and angiogenesis and inhibits bone resorption after bone marrow ablationBone20074028129217049330
   PubMed Web of Science ®Google Scholar
• OrimoHNakamuraTHosoiTJapanese 2011 guidelines for prevention and treatment of osteoporosis – executive summaryArch Osteoporos2012732023203733
   PubMedGoogle Scholar
• GallagherJCFowlerSEDetterJRShermanSSCombination treatment with estrogen and calcitriol in the prevention of age-related bone lossJ Clin Endocrinol Metab2001863618362811502787
   PubMed Web of Science ®Google Scholar
• ShikariMKushidaKYamazakiKNagaiTInoueTOrimoHEffects of 2 years’ treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective studyEndocr J1996432112209026268
   PubMed Web of Science ®Google Scholar
• O’DonnellSMoherDThomasKHanleyDACranneyASystematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and fallsJ Bone Miner Metab20082653154218979152
   PubMed Web of Science ®Google Scholar
• PapadimitropoulosEWellsGSheaBMeta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal womenEndocr Rev20022356056912202471
   PubMed Web of Science ®Google Scholar
• RingeJDSchachtEPotential of alfacalcidol for reducing increased risk of falls and fracturesRheumatol Int2009291177118519159932
   PubMed Web of Science ®Google Scholar
• UchiyamaYHiguchiYTakedaSED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosisBone20023058258811934649
   PubMed Web of Science ®Google Scholar
• MatsumotoTMikiTHaginoHA new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trialJ Clin Endocrinol Metab2005905031503615972580
   PubMed Web of Science ®Google Scholar
• MatsumotoTTakanoTYamakidoSTakahashiFTsujiNComparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolismJ Steroid Biochem Mol Biol201012126126420298784
   PubMed Web of Science ®Google Scholar
• MatsumotoTItoMHayashiYA new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures – a randomized, active comparator, double-blind studyBone20114960561221784190
   PubMed Web of Science ®Google Scholar
• ShirakiMSaitoHMatsumotoTEldecalcitol normalizes bone turnover markers regardless of their pre-treatment levelsCurr Med Res Opin2012281547155222794117
   PubMed Web of Science ®Google Scholar
• NakamuraTTakanoTFukunagaMShirakiMMatsumotoTEldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidolJ Bone Miner Metab20133141742223575909
   PubMed Web of Science ®Google Scholar
• HaginoHTakanoTFukunagaMShirakiMNakamuraTMatsumotoTEldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosisJ Bone Miner Metab20133118318923129180
   PubMed Web of Science ®Google Scholar
• Bischoff-FerrariHAKielDPDawson-HughesBDietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among US adultsJ Bone Miner Res20092493594219113911
   PubMed Web of Science ®Google Scholar
• MarwahaRKTandonNGargMKBone health in healthy Indian population aged 50 years and aboveOsteoporos Int2011222829283621271341
   PubMed Web of Science ®Google Scholar
• ReidIRBollandMJGreyAEffects of vitamin D supplements on bone mineral density: a systematic review and meta-analysisLancet201438314615524119980
   PubMed Web of Science ®Google Scholar
• DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) GroupPatient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and EuropeBMJ2010340b546320068257
   PubMed Web of Science ®Google Scholar
• AvenellAGillespieWJGillespieLDO’ConnellDVitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosisCochrane Database Syst Rev2009CD00022719370554
   PubMedGoogle Scholar
• IwamotoJ1SatoY2Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonatesTher Clin Risk Manag201410515924476669
   PubMed Web of Science ®Google Scholar
• SakaiAItoMTomomitsuTe-ADVANCED Study GroupEfficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosisOsteoporos Int20152631193120225592133
   PubMed Web of Science ®Google Scholar